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Adrenoceptor (AR)-linked pathways belong to the major components of
the stress response system and are associated with the pathophysiology of
diseases within the spectrum of metabolic syndrome. In this study, the role
of adrenoceptor stimulation in serum triglyceride (TG) regulation in mice
was investigated. For this purpose, a1-ARs were activated with phenyle-
phrine (PH) and b1/2-ARs with isoprenaline (ISOP). Both AR agonists
markedly reduced serum TG levels independently of PPARa activation.
These drugs also significantly activated the hormone-sensitive lipase in the
white adipose tissue indicating increased mobilization of TGs in this tissue.
In addition, PH and ISOP up-regulated Lpl, Nr4A, Dgat1, Mttp, Aadac
and Cd36 genes, critical in TG regulation, whereas the observed decrease
in serum TG levels was independent of the hepatic very low-density
lipoprotein (VLDL)-TG secretion. Interestingly, PH and ISOP also inacti-
vated the hepatic insulin/PI3k/AKT/FoxO1 signaling pathway, holding a
critical role in the regulation of genes involved in TG synthesis. Taken
together, the findings of the present study indicate that stimulation of a1-
and b1/2-ARs markedly reduced serum TG steady-state levels as a result of
alterations in TG synthesis, uptake, transport, hydrolysis, metabolism and
clearance, an effect induced by PPARa independent mechanisms.
Introduction
Hypertriglyceridemia is a major pathological feature of
metabolic syndrome, which is associated with the
accumulation of triglyceride-rich lipoproteins (TRLs)
in circulation. Patients with elevated serum TRLs are
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at high risk for cardiovascular and renal disease, as
well as for steatohepatitis and other disorders. To
date, treatment with fibrates is the most effective phar-
macological approach in clinical practice for the reduc-
tion of serum TG levels. Fibrates are used either as
monotherapy or in combination with statins and other
hypolipidemic drugs [1,2].
Fibrates are ligands for the peroxisome prolifera-
tor-activated receptor a (PPARa), which is acti-
vated by psychophysiological stress via stimulation
of AR-linked pathways and glucocorticoids [3,4].
PPARa acts as a cellular ‘lipostat’ that transduces
alterations in cellular lipid levels to the transcrip-
tional regulation of various target genes, which are
critical to the fate of fatty acids [5–7]. In particu-
lar, activation of PPARa up-regulates a broad
array of genes encoding enzymes that are involved
in fatty acid uptake, transport, as well as in mito-
chondrial and peroxisomal fatty acid b-oxidation
and microsomal fatty acid x-oxidation. In addition,
several apolipoproteins are regulated by PPARa
including apolipoproteins (Apo) AI, AII, and CIII,
a fact that indicates the central role of PPARa in
the extracellular transport and metabolism of TG-
rich lipoproteins in blood [3]. These PPARa-medi-
ated changes in gene expression result in reduced
serum TG-rich lipoproteins and increased high-den-
sity lipoprotein (HDL) levels [8,9], although the
exact mechanisms that link TG and HDL levels
are currently poorly defined.
The apparent causative relationship between serum
TRL levels and a wide range of human pathologies
has triggered the development of several biological
drugs targeting TRL metabolism, such as Volane-
sorsen, [10], Evinacumab [11–13], and IONIS-
ANGPTL3-LRx [14]. Nonetheless, the effective pre-
vention of hypertriglyceridemia requires a deeper
understanding of the biochemical mechanisms involved
and more precisely, the triggers leading to excess TRL
accumulation in serum.
The role of stress in the regulation of lipid home-
ostasis is well documented. In particular, chronic stress
deregulates lipid and carbohydrate homeostasis and is
considered as a causative factor of several pathologies
related to the metabolic syndrome, such as visceral
obesity, insulin resistance, dyslipidemia, dyscoagula-
tion, and hypertension [15–23]. It also has been
reported that humans with low-sympathetic nervous
system (SNS) activity, reduced beta-adrenergic sensitiv-
ity, and lipid mobilizing efficacy of catecholamines dis-
play lowered energy expenditure and are at high risk
to develop obesity compared to physiological subjects.
Therefore, adrenergic receptors, major components of
the SNS, have been considered as putative therapeutic
targets against obesity [24]. Accumulating evidence
also suggests that short-term exposure to stress has a
beneficial effect on TG regulation. Specifically, suba-
cute exposure to repeated restraint stress markedly
reduces serum TG steady-state levels, predominantly
via adrenergic receptor (AR)-linked pathways. In
particular, a1- and b1/2-ARs appear to hold major
roles in this regulation, as blockade of these recep-
tors prior to stress completely inhibited the suppres-
sive effect of stress on serum TG levels [4].
Activation of the hormone-sensitive lipase (HSL) in
the white adipose tissue (W.A.T.) by stress or epi-
nephrine, a major effector of the stress response, is
potentially responsible, at least in part, for this sup-
pressive effect. In addition, stress via stimulation of
a1- and b1/2-ARs up-regulated several genes in the
W.A.T., which are critical in the synthesis and metabo-
lism of TG depots, such as the diacylglycerol acyl-
transferase (Dgat)1 and 2, lipoprotein lipase (Lpl),
adipose triglyceride lipase/patatin-like phospholipase
domain containing 2 (Atgl/Pnpla2), arylacetamide
deacetylase (Aadac), microsomal triglyceride transfer
protein (Mttp), and the orphan nuclear receptor
(Nr4A) [2,25–32].
Το better understand the molecular mediators of the
stress-related hypertriglyceridemia, in this study, we
investigated the involvement of a1- and b1/2-ARs in
the regulation of serum TRL homeostasis. For this
purpose, pharmacological manipulations of a1- and b1/
2-AR–linked pathways by phenylephrine (PH) and iso-
prenaline (ISOP), respectively, were used. The data
revealed a strong suppressive effect of the b1/2-AR
agonist and less of the a1-AR agonist on serum TG
steady-state levels, independent of PPARa activation,
shedding light in novel-signaling pathways triggered by
the adrenergic system with significant roles in TRL
homeostasis.
Results
Alterations in serum lipid levels, post-prandial
triglyceride kinetics, and hepatic VLDL
triglyceride secretion
Pharmacological stimulation of a1-ARs markedly
reduced serum TG, free fatty acid (FFA) and total
cholesterol levels in wild-type mice (Fig. 1A–C). Beta-
AR stimulation decreased only serum TG and FFA
concentration, whereas it had no effect on total choles-
terol levels (Fig. 1A–C). Interestingly, stimulation of
ARs also suppressed serum TG steady-state levels in
Ppara-null mice thus indicating a PPARa-independent
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mechanism in TG regulation by PH and ISOP
(Fig. 1A). In an effort to provide a mechanistic inter-
pretation of the observed reduction in serum TG levels
following stimulation of ARs with AR-agonists, the
hepatic VLDL-TG secretion kinetics was determined
in control and AR-agonist–treated Ppara-null mice.
Stimulation of b1/b2-ARs with ISOP resulted in a sig-
nificant increase in the rate of hepatic VLDL-TG
secretion in treated mice when compared to controls
(Fig. 2A), while PH (a1-AR agonist) did not have
any significant effect (Fig. 2A), suggesting that mobi-
lization and secretion of hepatic TG into VLDL par-
ticles could not account for the observed reduction of
serum TG levels following PH treatment (Figs 1A
and 2A). Similarly, no significant changes in serum
AST, ALT and body weight levels were observed fol-
lowing the above mentioned drug treatments
(Tables 1 and 2).
In vivo assessment of the role of AR-related
pathways in TG regulation
To further elucidate the mechanisms underlying the
strong suppressive effect of AR-linked pathways on
serum TG steady-state levels, the expression of various
genes encoding factors involved in TG synthesis, meta-
bolism, and clearance were determined by qPCR and
western blot analysis. Both PH and ISOP increased
hepatic Lpl mRNA expression (Fig. 3A). Nr4A
mRNA expression was also increased by PH and ISOP
in the liver (Fig. 3). In contrast, the expression of
Atgl/Pnpla2, Hsl, and Aadac mRNAs were suppressed
by PH in this tissue (Fig. 3,B). Dgat2 mRNA tran-
scripts were also increased in the liver of PH- and
ISOP-treated mice (Fig. 3B), whereas Dgat1 mRNA
expression was not affected (Fig. 3A). Moreover,
Mttp, carboxylesterase 3 (Ces3/tgh) and cluster of dif-
ferentiation 36 (Cd36) mRNAs were increased to the
same extent in the liver of both, PH- and ISOP-treated
mice compared to placebo-treated animals (Fig. 3B).
No effect was observed on hepatic low-density lipopro-
tein receptor (Ldl-r) mRNA expression (Fig. 3C).
Similarly, APOE protein expression was not affected
by either AR agonists (Fig. 3C).
It is of interest to note that the AR agonists, PH, and
ISOP also up-regulated Nr4A in the W.A.T., which may
in turn trigger the up-regulation of Lpl (Fig. 4). Hsl and
Atgl/Pnpla2 mRNA and protein were not affected by
either PH or ISOP in this tissue (Fig. 4A and D). PH,
though, induced HSL phosphorylation at Ser563 in the
W.A.T. compared to controls (Fig. 4D), whereas ISOP
increased HSL phosphorylation at Ser660 in this tissue
(Fig. 4D). Notably, total perilipin and specifically,
PLIN5 protein levels were not modified by the AR ago-
nists in the W.A.T. (Fig. 4D). Dgat1 mRNA expression
was increased only by ISOP in the W.A.T. (Fig. 4A),
whereas Mttp and Cd36 were up-regulated by both
drugs (Fig. 4B). Ces3/tgh mRNA expression was not
affected (Fig. 4B). Interestingly, TG content in the
W.A.T. was lower in PH- and ISOP-treated mice com-
pared to controls (Fig. 1C). In contrast, TG levels were
higher in the livers of ISOP-treated mice compared to
controls and PH-treated animals (Fig. 2C).
In order to determine the role of AR agonists in
lipid b-oxidation, the effect of PH and ISOP on
mRNA encoding ACADM, the rate-limiting enzyme
of this reaction, was assessed in the liver and W.A.T.
using qPCR analysis. Only stimulation of a1-ARs with
PH markedly increased Acadm mRNA expression in
the liver compared to controls; ISOP had no effect
(Fig. 3C). In contrast, PH repressed Acadm mRNA
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Fig. 1. Effects of PH and ISOP treatment on serum lipid markers.
PH: phenylephrine (a1-AR agonist); ISOP: isoprenaline (b1/b2-AR
agonist). Values are expressed as mean  SEM, n: 5 per
treatment group and comparisons took place between controls and
drug-treated mice; *P < 0.05, **P < 0.01, ***P < 0.001.
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In vivo and in vitro assessment of the AR-
induced alterations in Hnf4a regulation
Stimulation of a1- or b1/2-ARs with PH or ISOP,
respectively, markedly increased Hnf4a mRNA and
HNF4a protein levels (Fig. 5A). The AR-induced
Hnf4a expression triggered the up-regulation of the
Hnf4a target genes, Cyp8b1 and bile acid CoA: amino
acid N-acyltransferase (Baat) (Fig. 5B). Further inves-
tigation revealed that the drug-induced up-regulating
effect on hepatic Hnf4a is due to a direct effect of the
drug on hepatocyte a1- or b1-ARs, respectively. Treat-
ment of primary hepatocytes with either PH or ISOP
markedly induced hepatocyte Hnf4a mRNA expression
(Fig. 5C). This up-regulating effect on Hnf4a was
blocked by pre-treatment of the cells with the PKA
inhibitor, H89, and the phosphatase- and ATPase
inhibitor, NaOV (Fig. 5C). The ISOP-induced Hnf4a
up-regulation was also prevented mainly, by the
phosphatase- and ATPase inhibitor, NaOV and to a
lesser extent by H89 (Fig. 5C).
In vivo assessment of the role of AR-linked
pathways in PI3k/AKT/FoxO1 and cAMP/PKA
activation
In order to further investigate the mechanism underly-
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Fig. 2. Effects of PH and ISOP treatment
on kinetic parameters of serum triglyceride
metabolism. Panel A shows the rate of
hepatic VLDL triglyceride secretion of the
PH- or ISOP-treated mice and controls and
Panel B represents the kinetics of post-
prandial triglyceride clearance in PH- and
ISOP-treated mice. Panel C shows TG
concentration in the liver and white adipose
tissue (W.A.T.) of mice following treatment
with either PH: phenylephrine (a1-AR
agonist), ISOP: isoprenaline (b1/2-AR
agonist) or normal saline (controls). Values
are expressed as mean  SEM, n: 5 per
treatment group and comparisons took
place between controls and drug-treated
mice. Group differences were calculated by
one-way ANOVA, followed by Bonferroni’s
test. All experiments were performed as
described in Materials and Methods.
*P < 0.05, **P < 0.01, ***P < 0.001.
Table 1. AR-induced alterations in serum ALT and AST concentration. Adrenergic receptor (AR); Alanine aminotransferase (ALT), aspartate
aminotransferase (AST), phenylephrine (PH), isoprenaline (ISOP), (wild-type, n = 20; Ppara-null, n = 15)
Wild-type Ppara null
Control PH ISOP Control PH ISOP
ALT 9.1  0.9 11.3  4.9 7.1  2.0 10.1  2.3 11.4  2.7 8.3  3.4
AST 25.2  4.6 29.5  11.2 15.5  2.0 24.6  5.3 28.2  8.9 18.9  2.7
Table 2. Alterations in the body weight following adrenergic
receptor agonist treatment
Treatment 1st day 4th day
Control 25.1  1.0 26.3  0.8
Phenylephrine 27.9  0.4 28.6  0.5
Isoprenaline 24.0  0.6 25.2  0.5
Body weight values are expressed in g. Phenylephrine, a1-adrener-
gic receptor (AR) agonist; Isoprenaline, b1/2-AR agonist.
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ISOP treatment, total cellular proteins were analyzed
by western blot. When compared to controls, both,
PH and ISOP reduced AKT and consequently, FoxO1
phosphorylation in the liver (Fig. 6), whereas they
increased CREB phosphorylation (Fig. 6), indicating
inactivation of the PI3k/AKT/FoxO1 and activation
of the AR/cAMP/PKA/CREB signaling pathway.
Discussion
Accumulated experience over the past many decades
of basic and clinical research established unequivocally
a major role of LDL-C in the development and pro-
gression of atherosclerosis. However, the aggressive













































































































































C           PH        ISOPC           PH         ISOP         
Fig. 3. Adrenergic receptor-mediated effect on hepatic factors regulating TG serum levels. (A) Effect of AR-agonists on genes involved in
TG synthesis and lipolysis in the liver. (B) Effect of AR-agonists on genes involved in TG metabolism and clearance in the liver. (C) Effect of
AR-agonists on factors important in lipid b-oxidation, the clearance of triglyceride-rich lipoproteins and the transport of free fatty acids.
Comparisons were between controls and drug-treated mice. Dgat1: diacyl glycerol acyltransferase, Dgat2: diacyl glycerol acyltransferase 2,
Lpl: lipoprotein lipase, Hsl: hormone-sensitive lipase, Atgl/Pnpla2: adipose triglyceride lipase/patatin-like phospholipase domain containing 2,
Nr4A: orphan nuclear receptor NR4A, Aadac: arylacetamide deacetylase, Cd36: cluster of differentiation 36 or fatty acid transporter, Ces3/
tgh: carboxylesterase 3, Mttp: microsomal triglyceride transfer, Acadm: acyl-CoA dehydrogenase, Ldl-r: low-density lipoprotein receptor,
ApoE: apolipoprotein E. In the western blot, three samples per treatment were loaded in three different blots. C: Control, phenylephrine (a1-
AR-agonist, PH), isoprenaline (b1/2-AR agonist, ISOP). Values are expressed as mean  SEM, n:5-6 mice per treatment group. Group
differences were calculated by one-way ANOVA, followed by Bonferroni’s test. *P < 0.05, **P < 0.01, ***P < 0.001.
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medications is still associated with substantial residual
cardiovascular risk, and strongly suggests that the ben-
efit from LDL-C lowering strategies has reached a pla-
teau [33]. Identifying and targeting alternative
processes that are highly associated with atherogenesis
may provide new ways to complement existing thera-
pies and augment their benefit against the development
of diseases, thus further reducing the residual cardio-
vascular risk, which is associated with the current
pharmacotherapy [33].
The apparent causative relationship between high-
TRL serum levels and atherosclerosis led to the
development of several investigational drugs currently
in clinical trials, that target TRL metabolism [33].
Volanesorsen, an apolipoprotein C3 (Apo C3) anti-
sense oligonucleotide, targets selectively Apo C3
mRNA and blocks protein synthesis, due to the
enhanced ribonuclease H1-mediated degradation of
Apo C3 mRNA [10]. Another experimental drug is
Evinacumab, an angiopoietin-like protein 3 (ANGPTL3)
monoclonal antibody that blocks ANGPTL3, a pro-
tein known to increase plasma TRL and TG levels
[11,34,35]. Another similar ANGPTL3-targeting drug





































































































































Fig. 4. Adrenergic receptor-mediated effect on various factors expressed in the W.A.T. regulating TG serum levels (A) Effect of
phenylephrine (a1-AR agonist, PH) and isoprenaline (b1/2-AR agonist, ISOP) on the expression of genes involved in TG synthesis and
lipolysis. (B) Effect of PH and ISOP on the expression of genes involved in TG metabolism and clearance. (C) Effect of PH and ISOP on
factors important in lipid b-oxidation, the clearance of triglyceride-rich lipoproteins and the transport of free fatty acids. Comparisons were
between controls and AR-agonist-exposed mice; Dgat1: diacyl glycerol acyltransferase 1 (acyl coenzyme A (CoA), Dgat2: diacyl glycerol
acyltransferase 2, Lpl: lipoprotein lipase, Hsl: hormone-sensitive lipase, Atgl/Pnpla2: adipose triglyceride lipase/patatin-like phospholipase
domain containing 2, Nr4a: orphan nuclear receptor, Aadac: arylacetamide deacetylase, Cd36: cluster of differentiation 36 or fatty acid
transporter, Ces3/tgh: carboxylesterase 3, Mttp: microsomal triglyceride transfer, PLIN5: perilipin 5, AR: adrenergic receptor, C: Control,
W.A.T.: white adipose tissue. Values are expressed as mean  SEM, n:5-6 mice per treatment group; Group differences were calculated by
one-way ANOVA, followed by Bonferroni’s test. *P < 0.05, **P < 0.01, ***P < 0.001. Lanes in western blots correspond to one sample
per treatment and represent one sample of three separate samples tested in different blots.
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antisense oligonucleotide. Despite these developments,
the molecular triggers that are associated with the dis-
ease development and eventually with the elevated
plasma, TRL accumulation remain largely unexplored.
There is a strong evidence that both, central and
peripheral nervous systems, may be involved in this
regulation [4,36–38].
Pharmacological stimulation of a1- or b1/2-AR–
linked pathways markedly reduce the steady-state
levels of serum TG in mice. These data are in line with
studies reporting that subacute repeated restraint stress
via mainly AR-related pathways reduces serum TG
levels [4]. Investigation of the potential mechanisms
involved in the AR agonist-induced serum TG reduc-
tion indicated that PPARa activation is not a part of
this mechanism, because treatment of Ppara-null mice
with either PH or ISOP triggered a reduction in serum
TG levels that was comparable with that observed in
PPARa expressing mice. Therefore, fibrates may not
be an effective therapy for the stress-related hyper-
triglyceridemia. The contribution of other molecular
factors, such as APO C3 and ANGPTL3, needs to be
investigated.
The significant reduction in serum FFA observed
following treatment with PH and ISOP may also sug-
gest that AR agonists potentially increase energy
requirements in the treated mice. This hypothesis is
supported by previous studies reporting that agents,
which stimulate adrenergic neurons increase energy
expenditure, lipolysis, and fat oxidation [24]. Free fatty
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Fig. 5. The effect of adrenergic receptor-related pathways on Hnf4a expression. (A) Following treatment with AR-agonists, hepatic Hnf4a
mRNA levels were analyzed in wild-type mice by qPCR. HNF4a protein was determined in liver nuclear fractions by western blot analysis.
Histone H3 served as a loading control. In the bar graph, the quantified data from the western blot image are shown presented as the ratio
of HNF4a/Histone H3. (B) Cyp8b1 and Baat mRNA levels were analyzed in livers of wild-type mice by qPCR following treatment with AR-
agonists. (C) Hnf4a mRNA levels were determined by qPCR following treatment of primary hepatocyte cultures with AR-agonists for
24 hours. Primary hepatocytes were also treated with AR-agonists in combination with either the JNK inhibitor, SP600125, the PKA
inhibitor, H89, or the phosphatase- and ATPase inhibitor, NaOV (concentration of the inhibitors in the medium:10 lM and duration of
incubation: 24 h). Values were normalized to b-actin and are expressed as mean  SEM (n = 8–10). In the in vivo experiment, comparisons
were between controls and drug-treated mice. In the in vitro experiment, comparisons were between DMSO and drug-treated hepatocytes,
(n = 3–4). AR: adrenergic receptor, C: control (DMSO-treated primary hepatocytes), PH: Phenylephrine (a1-AR agonist), ISOP: Isoprenaline
(b1/2-AR agonist). Group differences were calculated by one-way ANOVA, followed by Bonferroni’s test. *P < 0.025, **P < 0.01,
***P < 0.001.
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acids derived from TG b-oxidation are a major source
of energy. It is plausible that the rapid reduction in
serum TG levels observed in mice following treatment
with AR agonists represents an immediate uptake of
plasma TRLs by energy craving tissues in treated mice.
Circulating TRLs serve as an immediate source of
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Fig. 6. The role of adrenergic receptors in the activation of insulin/PI3k/AKT/FoxO1 and AR/cAMP/PKA/CREB signaling pathways. Total and
phosphorylated AKT and FoxO1 expression levels were examined in hepatic total cellular proteins using western blot analysis. CREB
phosphorylation was assessed in hepatic total cellular proteins. C: control, PH: phenylephrine (a1-AR agonist), ISOP: isoprenaline (b1/2-AR
agonist). The numbers next to the lanes represent the relative protein expression that is defined as the ratio between the drug-treated and
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Fig. 7. Hypothetical model summarizing the impact of a1- and b-AR agonists on HSL phosphorylation in the white adipose tissue and the
subsequent hepatic TG mobilization. The present data indicated that exposure to phenylephrine (PH, a1-AR agonist) activated the cAMP-PK (PKA)
resulting in HSL phosphorylation at Ser563, whereas the activation of PKA, induced by isoprenaline (ISOP, b1/2-AR agonist) led to phosphorylation
of HSL at Ser660. Both, PH and ISOP, also activated the AMP-activated kinase (AMPK), which is considered to block the PKA-dependent
activation of HSL in adipocytes, when HSL phosphorylation occurs at Ser563, while it is preserved when it occurs at Ser660. The current data
confirm the lesser significance of a1-ARs in the HSL-dependent lipolysis in adipocytes compared to that of b-ARs [42,44]. FFA: free fatty acids.
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FFA. However, since circulating TRLs represent a
limited supply, HSL activity needs to be stimulated in
order to mobilize additional intracellular deposits of
TGs for sustained energy production in the W.A.T.
In addition, given the complex and multifactorial
regulation of TG homeostasis, it is possible that AR
stimulation by PH and ISOP influences numerous and
diverse processes responsible for the observed reduc-
tion in serum TG levels. For example, PH and ISOP
treatment could affect dietary lipid absorption, their
packaging into chylomicrons, the processing of these
chylomicrons in plasma via lipoprotein lipase and their
subsequent clearance from the circulation by the LDL-
r, the tissue deposition and mobilization of these TGs
once they reach the respective tissues, their combustion
via b-oxidation of fatty acids, and their shuttling
between VLDL/LDL and HDL via CETP [25,26,30].
The precise effects of AR stimulation on these mecha-
nisms need further investigation.
The present data indicated that stimulation of a1- or
b1/2-ARs resulted in the up-regulation of several genes
holding determinant roles in the fate of TGs
[12,13,27,28,39,40]. In particular, AR agonists stimu-
lated the hepatic expression of genes encoding factors
involved in TG metabolism and clearance, including
Lpl, Nr4A, Mttp, Dgat2, Ces3/Tgh, and Cd36 [27,28].
These genes, with the exception of Ces3/Tgh and
Dgat2, were also increased in the W.A.T. Dgat1 was
up-regulated only by ISOP and Aadac only by PH in
the W.A.T. It is of interest also to note that both AR
agonists activated HSL in the W.A.T. and reduced TG
concentration in this tissue, indicating an increased
TG hydrolysis rate [12,13,27,28,39–41]. Treatment of
mice with either PH or ISOP promotes a considerable
decrease in serum TG levels. Notably, ISOP results in
a more significant effect. Real-time PCR analysis indi-
cated that both agonists induce Lpl expression, indicat-
ing that the suppressive effect of ISOP on serum TG
levels could be mainly due to increased Lpl expression;
the nuclear receptor NR4A may have triggered the
ISOP-induced Lpl up-regulation, while the effect of
PH on TG is mediated by downstream to LPL events
involved in the clearance of TG-rich lipoproteins, such
as enhanced holoparticle uptake by the LDL-r [26].
ISOP treatment significantly increased hepatic VLDL-
TG secretion, while PH had no effect, suggesting that
mobilization and secretion of hepatic TGs are not a
factor in the observed decrease in serum TG levels
shown in PH-treated mice.
Although the above findings are strongly indicative
for the role of AR agonists in the regulation of factors
determining the fate of TGs in the body, future studies
should be designed to pinpoint the AR agonist-induced
alterations in the aforementioned proteins, focusing
mainly in alterations at enzyme activity levels. It is
well-established that HSL activity is highly regulated
by adrenergic stimulation followed by PKA and
AMPK activation [42]. In cases where catecholamines
are physiologically elevated in humans (i.e,. during
physical exercise), the level of HSL phosphorylation at
Ser563 and Ser660 (PKA regulatory sites) is increased
in both, skeletal muscles and adipose tissue. This
induced phosphorylation results in HSL activation.
FFA released from the enzymatic lipolysis of W.A.T
triglycerides enters the hepatocytes where they are con-
verted into triglycerides that will be eventually incorpo-
rated into nascent VLDL particles [43]. Epinephrine,
an a/b-AR agonist, is known to induce phosphoryla-
tion of HSL at Ser563 and Ser660 to the same extent.
Our present data indicate that PH and ISOP differ
from epinephrine in that they selectively promote phos-
phorylation of either sites. Specifically, although PH
induced HSL phosphorylation at Ser563 in the W.A.T.
compared to controls (Fig. 4D), ISOP increased HSL
phosphorylation at Ser660 in this tissue (Fig. 4D).
Given that phosphorylation at both residues is required
for a significant induction of the HSL activity, and
based on the VLDL-TG secretion data (Fig. 2), we
hypothesize that the PH-induced Ser563 phosphoryla-
tion may be a weaker inducer of HSL activity, thus
resulting to less FFAs available for VLDL production
compared to those following the ISOP-induced Ser660
phosphorylation (Fig. 7). In support of our hypothesis
is the report that epinephrine (a/b-AR agonist), also
activates the AMP-activated kinase (AMPK), which is
considered to block the PKA-dependent activation of
HSL in adipocytes, when HSL phosphorylation occurs
at Ser563, while it is preserved when it occurs at
Ser660. Our data are in line with previous findings indi-
cating the lesser significance of a1-ARs in the HSL-de-
pendent lipolysis in adipocytes compared to that of b-
ARs [42,44]. Clearly, additional enzymatic studies are
essential to verify this hypothesis.
The increased fatty acid b-oxidation in the hepatic
mitochondria also profoundly contributes to the a1-
AR–induced decline in serum TG steady-state levels,
as PH led to an up-regulation of hepatic Acadm that
encodes the rate-limiting enzyme in this metabolic
pathway [12]. In the W.A.T., fatty acid b-oxidation
does not appear to participate in PH- and ISOP-in-
duced decline in serum TG levels as both AR agonists
had no effect on Ppara and Pparc expression, whereas
PH repressed Acadm in this tissue (Fig. 4C).
Notably, PH and ISOP significantly up-regulated
hepatic Hnf4a that holds determinant roles in a regu-
latory network required for the maintenance of the
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hepatocyte phenotype and the regulation of several
metabolic genes involved in lipid homeostasis. It is of
interest to also note that Hnf4a is acting in a coordi-
nating fashion with the transcription regulators, Ppara
and Pparc, on their downstream target genes encoding
factors important in fatty acid metabolism [9,12,45]. In
both cases of AR agonists, the Hnf4a induced expres-
sion appears to be mediated by the activation of sev-
eral phosphatase- and ATPase-linked signaling
pathways, as pre-treatment of hepatocytes with the
inhibitor of these enzymes, NaOV, drastically pre-
vented the up-regulating effect of PH and ISOP on
Hnf4a. The involvement of the a1/b-AR/cAMP/PKA
signaling pathway in this induction is also indicated by
the fact that the PKA inhibitor, H89, restricted the
drug-induced effect on Hnf4a.
It is well documented that the insulin/PI3k/AKT/
FoxO1 signaling pathway regulates several lipogenic
genes involved in TG synthesis [46,47]. Inactivation of
this signaling pathway was detected following stimula-
tion of a1-ARs with PH or b1/2-ARs with ISOP, sug-
gesting that this effect may be responsible, at least in
part, for the strong reduction in serum TG steady-state
levels that are observed following treatment with these
AR agonists.
Conclusion
The present data indicate that stimulation of a1- or b1/2-
AR can efficiently reduce serum TRL levels via stimula-
tion of TG hydrolysis, transport, metabolism and clear-
ance, as well as inhibition of hepatic TG synthesis.
Given that stress response includes adrenοceptor stimu-
lation, our data further support that the stress-induced
changes in serum TG levels are mediated by a1- and b1/
2-ARs [4] in a PPARa-independent fashion, further sup-
porting that PPARa activators, such as fibrates, may
not be effective in the treatment of stress-related hyper-
triglyceridemia. Additional research may identify these
PPARa-independent triggers providing alternative
pharmacological targets for new pharmacological enti-
ties that may complement current therapies.
Materials and methods
Animals
Adult male Ppara-null mice [48,49], 7–8 weeks old, grown
on the 129/SV background and strain-matched wild-type
littermate controls, raised at NIH Animal Center, were
used in this study. All mice followed a NIH-31 rodent
chow-based diet (Zeigler, Gardners, PA) and had an ad libi-
tum continuous access to drinking water. Five mice per
cage were housed under a standard 12-h light, 12-h dark
cycle, and all mice were monitored daily in order to detect
outward signs of distress or adverse health effects. All stud-
ies involving experimental animals were carried out in
accordance with the Institute of Laboratory Animal
Resources guidelines and were approved by the National
Cancer Institute Animal Care and Use Committee.
Drugs and treatment
Phenylephrine hydrochloride (Sigma-Aldrich; 2 mgkg1
i.p.; PH) and isoprenaline hydrochloride (Sigma-Aldrich;
2 mgkg1, i.p.; ISOP) were dissolved in normal saline and
administered two to three times a day and for four consec-
utive days (dosing regimen: Total 2-3-3-2 = 10 injections),
in order to stimulate a1-ARs and b1/2-ARs, respectively.
The selection of the dosing schedule of adrenergic receptor
agonists was based on the literature to achieve sufficient
stimulation of the adrenergic receptors [50]. The controls
received normal saline and mice were not fasted during
treatment. Two hours after the last drug treatment (3–
4 p.m.), mice were killed by carbon dioxide asphyxiation
and trunk blood was collected in BD Microtainer Serum
Separator Tubes (Becton, Dickinson and Company, USA)
for biochemical and hormonal analyses. Liver and white
adipose tissue (W.A.T.) samples were dissected for total
RNA, cellular and nuclear protein extraction and were kept
along with serum samples at 80 °C until assayed. Each
treatment group included five to six animals and the find-
ings were confirmed by three different experiments.
Quantitative real-time PCR
Total RNA was isolated from the liver and W.A.T. using
the Trizol reagent (Invitrogen, Carlsbad, CA) following the
manufacturer’s protocol. The concentration of total RNA
was determined spectrophotometrically. Quantitative real-
time PCR (qPCR) was performed with cDNA generated
from 1 lg total RNA using the SuperScript III reverse
transcriptase kit (Invitrogen). The gene-specific primers
were designed for qPCR using the PRIMER EXPRESS software
(Applied Biosystems, Foster City, CA). The sequences for
the forward and reverse primers used are shown in Table 3.
For the real-time reactions, the SYBR Green PCR master
mix (Applied Biosystems, Warrington, UK) was used.
These reactions were carried out using the ABI PRISM
7900 HT sequence detection system (Applied Biosystems).
The relative mRNA expression levels were normalized to b-
actin mRNA and the absolute levels were determined using
the comparative threshold cycle method.
Western blot analysis
Nuclear extracts of liver samples were used for the immu-
noblot analysis of PPARa and hepatocyte nuclear factor
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4a (HNF4a) protein expression. The NE-PER nuclear
extraction kit (Pierce, Rockford, IL) was used for the
preparation of these extracts. The phosphorylation of pro-
tein kinase B (Akt) and forkhead box protein O1 (FoxO1)
was assessed in total cellular proteins, while the phosphory-
lation of cAMP-response element-binding protein (CREB)
was analyzed in nuclear proteins. Drug-induced alterations
at hepatic ApoE protein levels were assessed in total cellu-
lar proteins. Alterations in the phosphorylation of HSL, in
total ATGL, perilipin 5 (PLIN5) and total perilipin
apoprotein levels were assessed in total cellular proteins
extracted from the W.A.T. The BCA protein assay (Pierce,
Rockford, IL) was used for the determination of protein
concentrations. Proteins were subjected to sodium dodecyl
sulfate-polyacrylamide gel electrophoresis and immunoblot-
ting using the following antibodies: goat polyclonal HNF4a
IgG (Santa Cruz Biotechnology), rabbit polyclonal phos-
pho-AKT IgG (Ser473; Santa Cruz Biotechnology), rabbit
polyclonal phospho-FOXO1 (Ser256; Santa Cruz Biotech-
nology), rabbit polyclonal phospho-CREB-1 IgG (Ser133;
Santa Cruz Biotechnology), and rabbit monoclonal anti-
mouse ApoE IgG (Meridian USA). In addition, the rabbit
polyclonal phospho-HSL (Ser563, Ser565, Ser660) and total
HSL and Perilipin IgGs were also used (Lipolysis Activation
Antibody Sampler kit, Cell Signaling). The goat polyclonal
PLIN5 and ATGL IgGs, as well as the rabbit polyclonal
AKT, FOXO1, and CREB IgGs (Santa Cruz Biotechnol-
ogy) were also used. As loading control the immunoblotting
with mouse b-actin, Histone-H3 and GAPDH antibodies
(Santa Cruz Biotechnology) were used. The anti-rabbit, anti-
goat, or anti-mouse IgG horseradish peroxidase-conjugated
antibodies (Cell Signaling Technology) were used as sec-
ondary antibodies and the proteins were detected using an
enhanced chemiluminescence detection kit (Thermo Scien-
tific-Pierce, Rockford, IL). All western blot images were
submitted to quantitation using the Image Processing and
Analysis in Java soft ware (Image J).
Preparation of hepatocyte cultures
For the in vitro experiment, hepatocytes were prepared fol-
lowing a modified method based on a previous report [51].
In brief, for the isolation of parenchymal hepatocytes the
in situ perfusion of the murine liver was used. The isolated
hepatocytes were suspended in Williams’ Medium E supple-
mented with L-glutamine, penicillin, and streptomycin and
then, they were plated at a density of 0.80–1.0 9106 cells in
60 mm diameter collagen type I coated dish (BIOCOAT,
Cell Environment, Becton Dickinson Labware, UK). The
trypan blue dye exclusion was used to check the viability of
isolated cells. Only primary hepatocytes with viability higher
than 85% just before plating were cultured at 37 °C for
24 h under an atmosphere of humidified 5% CO2 in order
to allow the cells to adhere to the dish. Time and dose
response experiments started 24 hours later. The cells were
cultured in the presence of either AR agonists, PH or ISOP,
at different doses (1–100 lM) and for a period of time raging
from 4 to 36 hours. Here are presented only data from the
incubation of primary hepatocytes with the AR agonists at
a concentration of 25 lM for 24-h, as they clearly indicate
the direct effect of PH and ISOP on Hnf4a expression.
Determination of post-prandial triglyceride
kinetics following oral administration of olive oil
In order to compare the effect of AR-agonist treatment on
the post-prandial triglyceride kinetics, groups of 6-8 mice
were used. The determination of the post-prandial triglyceride
kinetics was performed as previously described [52,53]. Values
are expressed in mgdL1  standard error of the mean.
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Rate of hepatic very low-density triglyceride
production in mice treated with phenylephrine or
isoprenaline
In order to assess the effects of AR-agonist treatment on
hepatic VLDL triglyceride secretion, 6–8 mice per treatment
group were used. Briefly, treated mice were injected intraperi-
toneally with Triton-WR1339 at a dose of 500 mgkg1 b.w,
using a 15% solution (w/v) in 0.9% NaCl. Triton-WR 1339
inhibits completely VLDL catabolism, as previously
described [29,31]. Serum samples were collected 90 min fol-
lowing the injection with Triton WR 1339, in order to mini-
mize the influence of handling stress on the tested mice. As a
baseline control, serum samples were collected 1 min follow-
ing the injection with the detergent. Then, serum TG levels
were determined again at 90 min post-injection and linear
graphs of TG concentration vs time were generated. The rate
of VLDL triglyceride secretion (expressed in mgdL1min1)
was calculated from the slope of the linear graphs for each
individual mouse. The slopes were grouped together and
plotted in a bar graph as mean  standard error of the mean.
Statistical analysis was performed using the Student t-test.
Determination of total hepatic cholesterol and
triglyceride content
Tissue triglyceride determination was performed following
the method previously described by Karavia et al. [53].
Results are expressed as milligram (mg) of triglycerides per
gram of tissue  standard error of the mean.
Hormonal and biochemical determinations
Serum total cholesterol levels were measured using the
Cholesterol EIA kit (Wako Diagnostics, Richmond, VA)
and the levels of serum non-esterified fatty acids were
determined using the NEFA C, EIA kit (Wako Chemicals
GmbH, Neuss, Germany).
Serum triglyceride levels were analyzed using the GPO-
Trinder Kit (Sigma). In brief, the serum sample (10 lL)
was diluted in 40 lL Phosphate buffered saline (PBS), and
the dilute sample (7,5 lL) was analyzed for triglycerides,
following the manufacturer’s instructions. Triglyceride con-
centrations were determined spectrophotometrically at
540 nm as previously described [54].
Serum alanine aminotransferase (ALT) and aspartate
aminotransferase (AST) [17] levels were determined using
the Discrete Pak ALT and AST Reagents kits (Catachem
Inc, Bridgeport, CT).
Statistical analysis
The data of the present study are presented as the mean 
SE and were analyzed using the one-way analysis of vari-
ance (ANOVA) that was followed by multiple comparisons
with Bonferroni’s and Tukey’s least honest significant dif-
ference methods. The significance level for all analyses was
set at probability of less than 0.05.
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